ChineseNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CDA Technology Detects Risk of Over 25 Different Cancer Types
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a recognized innovator and leader in the field of early cancer screening and detection. Its core product and proven revenue generator, the pioneering Cancer Differentiation Analysis (“CDA”) platform, offers novel capabilities by looking for signals to help it assess the risk of cancer occurring before a tumor has developed. This approach is unlike the blood sample-based cancer screenings, which generally target protein-based biomarkers, genomic signals, such as circulating tumor DNA (“ct-DNA”), circulating in the bloodstream to determine if a cancer exists and is spreading.…

